Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy

  • Technology appraisal guidance
  • TA242
  • Published: 

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): review decision - March 2015

The Institute was proposing that TA242 should move to the ‘static guidance list’, and that the termination advice for TA240 should remain in place.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, TA242 will move to the ‘static guidance list’. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations. The termination advice for TA240 will remain in place.

March 2015

This page was last updated: 25 March 2015